EDMONTON, Alberta--(BUSINESS WIRE)--Nov. 3, 2005--ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that Rob Salmon, Chief Financial Officer ("CFO") of the Company has left ViRexx Medical Corp. to pursue other opportunities effective November 2nd, 2005. Marc Canton, President and Chief Operating Officer will assume the responsibilities of the CFO position on an acting basis.
